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Abstract
Background: Glaucoma is the leading cause of irreversible blindness in the world. Estimated to affect 60 million
people worldwide, this figure is expected to rise to 80 million by 2020. Untreated, glaucoma leads to visual decay
and eventually to blindness, and can significantly reduce quality of life. First-line treatment in patients with primary
open-angle glaucoma and exfoliative glaucoma is topical medical therapy with ocular hypotensives as eye drops.
However, eye drops have several disadvantages including cost, possible local and systemic side effects, and adherence
and perseverance issues. Randomised controlled trials have demonstrated that selective laser trabeculoplasty is equally
as effective in lowering intraocular pressure as eye drops. However, the impact of these two treatment modalities from
the patient and economic perspectives has not been adequately determined. Thus, it remains unclear whether topical
medical therapy or selective laser trabeculoplasty should be recommended as first-line treatment for glaucoma.
Methods/Design: This protocol describes an international, multi-centre, randomised controlled trial to determine
the optimum first-line therapy for people with primary open-angle glaucoma and exfoliative glaucoma. This study
will compare the effect of selective laser trabeculoplasty and topical medication with respect to patients’ generic and
glaucoma-specific quality of life. The trial will also provide a detailed cost-effectiveness analysis and compare
the clinical effectiveness with respect to the degree of intraocular pressure lowering and rates of treatment failure.
Research coordinators in each centre will identify and recruit previously untreated patients with primary open-angle
glaucoma and exfoliative glaucoma. Those who meet the eligibility criteria will be invited to enter a randomised
controlled trial with either selective laser trabeculoplasty or topical ocular hypotensive therapy, according to a stepped
regimen. Outcome assessment will be measured at 6 weeks and at 6, 12, and 24 months post-treatment. Regular clinic
follow-ups will continue as clinically indicated between study outcome visits.
Discussion: The Glaucoma Initial Treatment Study is the first multi-centred RCT to determine the optimum first-line
therapy for people with glaucoma. Our trial will have an unprecedented capacity to meaningfully transform the
treatment and management of glaucoma in Australia and overseas.
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Background
Glaucoma is the leading cause of irreversible blindness
in the world [1]. Estimated to affect 60 million people
worldwide, this figure is expected to rise to 80 million
by 2020 [2]. Glaucoma represents a group of optic neu-
ropathies characterised by a progressive degeneration of
retinal ganglion cells and their axons resulting in struc-
tural changes of the optic nerve and retinal nerve fibre
layer with concomitant patterns of visual loss. Untreated,
glaucoma leads to visual decay and eventually to blind-
ness, although less severe glaucoma can also significantly
reduce quality of life (QoL) and cause economic burden
to both the individual and society [3–5].
The pathophysiology and factors contributing to the
onset and progression of glaucoma are not fully under-
stood. Reduction in intraocular pressure (IOP) is the
only modifiable risk factor known to delay glaucoma on-
set and progression [6]. IOP is regulated by a balance
between the rates of aqueous humour secretion by the
ciliary body epithelium and its drainage via the trabecu-
lar meshwork and uveoscleral outflow pathways. First-
line treatment in patients with glaucoma is topical med-
ical therapy with ocular hypotensives as eye drops. These
either increase the aqueous outflow (such as prostaglan-
din analogues) or reduce aqueous production (such as
beta-adrenergic antagonists). Topical medical therapy
effectively lowers the IOP [6] but has limitations and
disadvantages including cost, possible local and systemic
side effects, adherence and perseverance issues, physical
barriers to self-instillation (such as tremor or arthritis)
and the prospect of daily and often life-long commit-
ment to medications [7–21].
The use of laser trabeculoplasty to lower IOP has pro-
vided an alternative strategy to treat glaucoma. One of
the laser trabeculoplasty modalities is selective laser trabe-
culoplasty (SLT), which utilises a Q-switched, frequency-
doubled Nd:YAG (532 nm) laser. It lowers IOP in patients
with glaucoma by enhancing aqueous outflow through the
trabecular meshwork, but the exact mechanism under-
lying the effectiveness of SLT remains uncertain. SLT has
been shown to recruit monocytes to the trabecular
meshwork and induce disassembly of tight junctions in
Schlemm’s canal cells [22, 23]. In comparison with older
laser trabeculoplasty techniques, SLT induces less coagu-
lative damage and structural change to the meshwork and
is potentially repeatable [24]. However, the effect of SLT
diminishes over time and it may be associated with local
adverse effects such as post-laser inflammation and tem-
porary elevations in IOP.
Studies comparing these treatments have demonstrated
no significant differences between prostaglandin eye drops
and SLT in lowering IOP [25, 26], although one study
showed that the prostaglandin analogue latanoprost con-
trolled IOP fluctuations better than SLT [27]. From the
societal perspective, a published cost-analysis found SLT
to be less costly than most brand-name topical medica-
tions within 1 year and less costly than generic latanoprost
and generic timolol (beta-adrenergic antagonist) after 13
and 40 months, respectively [28].
Although these studies have indicated that SLT and
topical prostaglandins are equally effective in lowering
IOP, they were generally underpowered and did not
consider the impact of these two treatment modalities
from the patient and economic perspectives. Glaucoma
patients can experience reduced QoL due to associated
functional loss; emotional and social implications; and
the inconvenience, side effects and cost of treatment
[3, 4, 29–34]. Thus, it remains unclear whether topical
medical therapy or SLT should be recommended as
first-line treatment for glaucoma with corresponding
improvements in QoL and economic benefits.
Objectives and hypotheses
We are implementing a multi-centre randomised con-
trolled trial (RCT) to determine the optimal first-line
therapy for people with primary open-angle glaucoma
(POAG) and exfoliative glaucoma (XFG). Our primary
endpoint will be health-related QoL (HRQOL). This study
will evaluate treatment outcomes with respect to patient
QoL, provide a detailed economic effectiveness analysis,
and compare the clinical effectiveness in terms of the de-
gree of IOP lowering and rates of treatment failure.
We hypothesise that treatment with SLT, compared with
topical medication, will improve overall and glaucoma-
specific QoL parameters, show comparable IOP reduction
and demonstrate less ocular and systemic side effects, in-
cluding less frequent ocular surface disease. We postulate
that SLT treatment is more cost-effective than topical
medical therapy in the treatment of POAG and XFG.
Specific aims
Aim 1: Our first aim is to compare the effect of SLT and
topical medication on glaucoma-specific QoL at 6 weeks
and at 6, 12, and 24 months post-treatment (primary
outcome).
Aim 2: Our second aim is to quantify the cost-
effectiveness of SLT treatment compared with glaucoma
medication treatment.
Aim 3: Our third aim is to determine factors associ-
ated with treatment outcomes at 12 and 24 months post-
SLT, including the rate of IOP success, defined as >25 %
reduction in IOP from baseline measurements.
Aim 4: Our final aim is to assess the impact of SLT
and eye drops on safety, laser-linked complications, and
common side effects for glaucoma patients after the
initiation of treatment.
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Methods/Design
The Glaucoma Initial Treatment Study (GITS) is a multi-
centred, cluster randomised, controlled, clinical trial com-
paring two treatments for patients with POAG and XFG.
Treating investigators and patients are not masked to
treatment allocation due to the nature of the treat-
ments; however, the QoL questionnaire administrators
are masked to treatment allocation.
Inclusion and exclusion criteria
Inclusion criteria
Inclusion criteria are as follows:
1. 35 years of age and above.
2. Previously untreated patients with either POAG or
XFG that, in the investigator’s opinion, warrants
IOP-lowering treatment.
3. Visual field - mean deviation (MD) values between
0 and -12 dB at baseline in the study eye on the
Humphrey Visual Field Analyser.
4. Optic disc changes consistent with glaucoma
including rim loss, nerve fibre layer defects (NFLD),
and disc haemorrhages.
Exclusion criteria
1. History or evidence of glaucoma other than POAG
or XFG.
2. Advanced glaucomatous field loss with MD
> -12 dB.
3. History of use of topical or systemic ocular
hypotensive medication(s).
4. Previous intraocular surgery (including glaucoma
laser or glaucoma surgery), with the exception
of uncomplicated phacoemulsification that did
not require additional intervention for
complications.
5. Iridotrabecular drainage angle anomalies.
6. Evidence of moderate non-proliferative diabetic ret-
inopathy or worse, neovascularisation or rubeosis
iridis.
7. Current use of a systemic corticosteroid,
epinephrine or clonidine.
8. Patients, who in the opinion of the investigator, are
at high risk of suffering symptomatic vision loss
and/or may require glaucoma surgery within the
2-year follow-up to the study.
9. Patients who are pregnant or currently breastfeeding
and/or planning to become pregnant within the
study period.
10.Patients who have a condition or are in a situation,
which, in the investigator’s opinion may put them at
significant risk or may interfere significantly with the
patient’s participation in the study.
Written informed consent will be collected from each
participant prior to inclusion in the study.
Interventions
Patients will be randomised 1:1 to treatment with either
SLT or topical ocular hypotensive therapy, according to
a stepped regimen (Figs. 1 and 2). If both eyes meet the
inclusion criteria, the eye with the highest IOP will be
enrolled in the study. However, both eyes will receive
the same treatment initially. If both eyes have the same
level of IOP, it will be at the investigator’s discretion to
choose the study eye based on visual fields and optic
disc evaluation.
Selective laser trabeculoplasty
For patients assigned to the SLT treatment arm, a sin-
gle application of pilocarpine (1 %) and apraclonidine
(1 %) or brimonidine (0.2 % or 0.15 %) will be instilled
into the operative eye prior to the laser (Fig. 1). A fre-
quency doubled, q-switched Nd:YAG laser emitting at
532 nm with a pulse duration of 3 ns, a spot size of 400
μm, and pulse energies ranging from 0.2 to 1.7 mJ,
coupled to a slit lamp delivery system with a helium-
neon laser aiming system will be used in all cases. Any
mirrored gonioscopic lens that does not magnify is
acceptable for use during the procedure. The laser will
be focused on the trabecular meshwork using the HeNe
aiming beams and a single laser pulse will be delivered
at the 3 o’clock position. The laser energy will be
increased or reduced by 0.1-mJ increments until fine
‘champagne’ bubbles are generated. During laser appli-
cation, bubble formation will be monitored with each
pulse to avoid excessive bubble formation and to avoid
no observed response.
Initial 180° treatments of approximately 50 applica-
tions will be applied inferiorly from the 3 to 9 o’clock
position. The total number of pulses delivered and the
total amount of energy delivered will be recorded follow-
ing each treatment. Participants will return for review of
treatment response in 6 weeks from the baseline treat-
ment and will then follow a stepped regimen, depending
on their response to treatment. If a second SLT treat-
ment is required, it will be applied over 180° from the 9 to
3 o’clock positions (superiorly). Treatment changes may
also be initiated if there is an adverse event post-treatment
and if this is considered severe enough to warrant a
change in treatment.
Topical ocular hypotensive therapy
Patients randomised to the topical medication treatment
group will be initially prescribed, where possible, a pros-
taglandin analogue with one drop to be instilled in each
eye (or the study eye only if only one eye is enrolled)
once daily (Fig. 2). We will instruct patients on how and
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when to instil their drops and stress the importance of
adherence. Patients will return for review of treatment
response 6 weeks from the baseline initiation of treat-
ment and will follow a stepped regimen, depending on
their response. We will change treatment if there is an
adverse event that is considered severe enough to war-
rant such change or if there is progression in visual field
loss or optic disc changes. Treatment response will be
defined as follows:
1. Successful response ≥25 % IOP reduction compared
with baselines.
2. Partial response = 10-25 % IOP reduction compared
with baselines.
3. No response = ≤10 % IOP reduction compared with
baselines.
If patients have crossed over with both treatment regi-
mens, they will exit the trial with further management at
the discretion of the treating doctor (Figs. 1 and 2).
Based on the grading system developed by the Collab-
orative Initial Glaucoma Treatment Study (CIGTS) [35],
optic discs will be clinically analysed for the following
characteristics: (a) vertical and horizontal central cup to
disc ratio; (b) focal and diffuse thinning of neuro-retinal
rim; (c) presence of a disc haemorrhage; (d) nerve fibre
layer defects; and (e) extent of peripapillary atrophy. If a
change in treatment is deemed necessary and urgent, it
may be initiated by the site investigator although the im-
ages would be reviewed by the Optic Disc Outcomes
Committee (ODOC), masked to the treatment allocation
(and initially the temporal sequence of the photos) to
validate treatment change. For all disc changes consid-
ered non-urgent, these images will be referred to the
ODOC where it will be the final arbiter on the presence/
absence of optic disc changes and any alteration to treat-
ment regimens. Visual field progression will be defined
according to the following criteria identified by the
Glaucoma Progression Alert on the Humphrey Visual
Field result:
1. Possible progression = 3 or more points show
deterioration on at least 2 consecutive visits.
2. Likely Progression = 3 or more points show
deterioration on at least 3 consecutive visits.
3. No progression detected = none of the above
conditions is met.
At each visit, the patient’s visual field results will be
reviewed and evidence of progression will be initially
determined by the Guided Progression Analysis (GPA)
alert and the site investigator. If the alert message is that
Fig. 1 Selective laser trabeculoplasty (SLT) treatment regimen: participants will follow a stepped treatment regimen, depending on their response
to treatment. App=applications; BL=baseline; IOP=intraocular pressure; SLT=selective laser trabeculoplasty
Lamoureux et al. Trials  (2015) 16:406 Page 4 of 10
of ‘Possible Progression’, then the visual fields will be for-
warded to the Visual Field Outcomes Committee (VFOC),
masked to the treatment administered to the patient. This
committee will make the final determination on the pres-
ence/absence of progression and change to treatment regi-
mens. If, however, the alert message is that of ‘Likely
progression’, the investigator is permitted to change/alter
treatment and then refer the fields to the VFOC to con-
firm this progression.
Randomisation
Randomisation schedules developed by the Centre for Eye
Research Australia (CERA) Melbourne, (Coordinating
Centre), using a list of computer generated pseudo-random
numbers are designed to yield an assignment ratio of 1:1.
Randomisation, per person, will be stratified by clinical
centre and type of glaucoma. The randomization number
will be assigned to a patient sequentially according to the
order of enrolment within the stratum. The treatment as-
signment form, contained in an opaque envelope will be
filed in the patient’s ‘Unmasked study folder’ with the pa-
tient’s screening code completed on this form. Sites will
then scan a copy of the treatment assignment and email
this to the Coordinating Centre for its records. When the
number of envelopes on site reaches only four remaining,
the site will notify the Coordinating Centre, which will send
more envelopes containing treatment allocations.
Allocation concealment
Each study site will receive a block of sequentially num-
bered, sealed, and opaque envelopes containing treatment
allocation for either ‘SLT’ or ‘Drops’. Opaque envelopes
will be opened in order of sequence per site. A unique
study code will be assigned to each patient at randomisa-
tion, consisting of a three-digit randomisation number
along with the patient’s initials.
Outcome measures
Health-related QoL (HRQOL)
Considering (a) the substantial side effects of topical
medication(s) and poor adherence and (b) its consider-
able impact on daily living and QoL, HRQoL parameters
are our critical outcomes to determine the treatment of
choice for glaucoma. The primary patient-centred out-
come will be assessed by significant changes in two
glaucoma-specific scales and one generic HRQoL instru-
ment at 6 weeks and at 6, 12, and 24 months post-
treatment. These tools include the following:
Fig. 2 Topical medication treatment regimen: participants will follow a stepped treatment regimen, depending on their response
to treatment. BL=baseline; IOP=intraocular pressure; SLT=selective laser trabeculoplasty
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1. Glaucoma Outcome Assessment Tool (GOAT): We
have developed a glaucoma-specific QoL item bank,
GOAT, which contains 342 items across 10 specific
QoL domains [36]. An item bank is a pool of calibrated
items that measure a defined underlying trait such as
QoL and becomes operational by the use of computer
adaptive testing [37].
2. The Glau-QoL questionnaire: The Glau-QoL is a
comprehensive glaucoma-specific QoL instrument
and has been validated in patients with glaucoma [38].
3. The AQoL-7D: The AQoL-7D is a health-related
multi-attribute utility instrument to assess QoL
[39, 40]. This descriptive system comprises seven
domains describing QoL (including vision) with
levels of increasing severity. A scoring algorithm,
based on general population values for health states
defined by the descriptive system, is used to assign
utilities to each health state (domain) described by
the instrument and overall QoL. The AQoL-7D has
been used in several RCTs in Australia and its overall
and subscale measures have been found to be sensitive
to interventions [41–44]. All QoL outcome measures
will be interviewer-administered.
Clinical
Clinical secondary outcomes will be determined by the
success rates of IOP reduction (defined as >25 % fall in
IOP from baseline), changes in the visual field and optic
disc from baseline to 24 months. The times required to
reach these changes will be reported. Changes in the
optic nerve head will be based on rim thinning, haemor-
rhage, or an increase in cup to disc (C/D) ratio and vis-
ual field changes based on progression.
Statistical analysis plan
All data analyses will be conducted according to a pre-
specified analytical plan using Stata version 12.1.0 (Stata
Corp, College Station, TX). All hypothesis testing will be
performed at the 5 % two-sided significance level. Analyses
and data summaries will be carried out using the intention
to treat (ITT) population. The ITT population is defined as
all patients registered for active follow-up regardless of
non-adherence with the intervention. All patients will be
analysed according to the intervention that they were
randomised to. A per-protocol analysis will be considered if
there are a considerable number of protocol violators.
Baseline characteristics
Analyses will be performed for all variables at baseline
to detect potential bias in recruitment. Continuous vari-
ables will be reported using means ± standard deviations
(SD) or median (interquartile range (IQR)). For dichot-
omous/categorical variables, absolute numbers and per-
centages will be computed, together with their 95 %
confidence intervals (CI). The comparison of means will
be carried out using Student’s t test, the Mann-Whitney
test, analysis of variance or the Kruskall-Wallis test as
appropriate. The difference in proportions between the
two treatment groups will be carried out using Chi-
square statistics. These comparisons will be made by
assessing the prognostic relevance of the difference
observed, not through hypothesis testing. Baseline sum-
maries with respect to the main covariates will be
presented and discussed from a clinical point of view,
irrespective of whether a statistical test indicated a
‘statistically significant difference’ between treatment
groups. If we find a strong baseline imbalance in a vari-
able, we will include this variable as a covariate in a
sensitivity analysis to allow assessment of the robustness
of the conclusions drawn from the primary analysis.
Primary analysis
The primary analysis will be ITT analysis, which in-
cludes all randomised patients in the groups to which
they were randomly assigned, regardless of their adher-
ence with the entry criteria, the treatment they actually
received, and of subsequent withdrawal from treatment
or deviation from the protocol. The ITT analysis will
include all patients with 24-month GOAT, Glau-QoL,
and AQoL-7D data. The GOAT will be our main
primary outcome. The GOAT and Glau-QoL data will
initially undergo Rasch Analysis (a form of Item Re-
sponse Theory - IRT) using Winsteps software (version
3.90), Chicago, Illinois [45].
We will examine the missing data mechanism (probabil-
ity distribution of missingness) to determine whether it is
missing completely at random (MCAR), missing at
random (MCR) or missing not at random (NMAR). Since
patient-centred measurements will recur on the same
patients, longitudinal HRQoL data will be analysed using
multivariate generalised estimating equation (GEE) or
generalized linear mixed models (GLMMs). We will adjust
for pre-defined variables that we consider are associated
with the primary outcome (HRQoL) from the literature.
These include clinical variables (for example, baseline
glaucoma severity, visual field, visual acuity, optic disc
changes, duration of glaucoma), and sociodemographic
variables (for example, age, gender). Separate regressions
will be conducted for each QoL parameter. These models
take into account the correlation within observations on
the same subject and allow for inclusion of data on sub-
jects who have only partial follow-up without imputing
missing data. To handle multiplicity in the multiple re-
gression models, Bonferroni adjustment will be used.
Economic analysis
The purpose of the economic evaluation is to examine
the incremental cost-effectiveness of SLT relative to
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medical care. Costs will be quantified from the health
system perspective using an activity based costing ap-
proach. Sunk costs will be excluded from the analysis.
Effectiveness will be defined in terms of the AQoL-7D
utilities. Once costs and effectiveness are known for each
intervention arm at both baseline and follow-up, the ap-
proach for quantifying cost-effectiveness will follow that
described in the literature [46]. As is common practice,
incremental cost-effectiveness ratios will be compared
with common thresholds adopted by National Institute
for Health and Care Excellence (NICE) and World
Health Organisation (WHO) for what represents good
value for money. In addition to quantifying this ratio, we
will also conduct one-way and n-way sensitivity analyses
and produce cost effectiveness acceptability curves
(CEAC) to show the probability that SLT is cost-
effective for a range of monetary values that a decision-
maker might be willing to pay for a unit change in qual-
ity adjusted life year (QALYs). Finally, because much of
the costs of SLT are one-time fixed costs, and topical
medication(s) is a recurring cost, if the results show SLT
to be at least as effective as topical medication, the aver-
age time it takes for SLT to become a dominant strategy
will also be quantified. All analyses will be conducted
using TreeAge software.
Clinical efficacy
To assess clinical efficacy (IOP reduction success), Chi
square tests will be used and multivariable logistic re-
gression models with odds ratios (OR) and 95 % CI will
be built. Other analyses will be tailored to the nature of
the secondary outcome data. Numerical data (for ex-
ample, IOP and visual acuity) and dichotomous data
(presence/absence) will be analysed by the GEE. Survival
data (for example, time-to-VF (visual field) progression,
IOP becoming uncontrolled again) will be analysed using
survival analysis. Stepwise multiple regression analyses
for secondary outcomes will evaluate a similar set of po-
tential explanatory factors (covariates) in addition to
treatment assignment and those evaluated for the primary
analysis. Time-varying covariates will be used for analyses
evaluating repeated measures of the outcome, if appropri-
ate. Standard errors of estimates from log-linear models
will take account of possible over-dispersion with respect
to the assumed models.
To determine the impact of SLT (single or multiple
applications) on safety, surgical complications, and com-
mon side effects associated with glaucoma treatment,
Chi square tests will be used initially and regression
models with ORs and 95 % CI will be built. Where ap-
propriate, Poisson regression will be used to compare
event rates (for example, adverse events). To determine
the predictors of IOP reduction success, survival curves
will be constructed using the Kaplan-Meier method. Cox
proportional hazards method will be used to adjust for
confounders. Hazard ratios (HR) with 95 % CI will be
provided to estimate the relative risk.
Planned subgroup analyses
Analyses for the primary (HRQoL) and secondary out-
comes (clinical efficacy) will be stratified for baseline
types of glaucoma (POAG and XFG).
Sample size estimation
The sample size for the study is based on the primary out-
come measure of HRQoL at 24 months post-treatment.
Our hypothesis is that compared with topical medication,
SLT treatment will have a significantly greater positive im-
pact on HRQoL. Mean and standard deviations for the
pilot data of GOAT and previous work with the Glau-QoL
were used [36, 38]. To detect a 0.156 Logit difference (ef-
fect size of 0.3) on the Rasch-analysed GOAT and Glau-
QoL at 80 % power with a 5 % level of significance, 175
patients will be needed in each group. Similarly, the mean
and standard deviation values for the AQoL-7D were ob-
tained from the literature [39, 47]. To detect a 0.7 differ-
ence (effect size of 0.3) on the AQoL-7D between the two
groups at 24 months with 80 % power at 5 % level of
significance; 176 patients will be needed for each group.
Assuming an attrition rate of 15 % after 2 years, 193
patients will be enrolled in each group at baseline. Fur-
thermore, for Aim 3, the study will also have 79 % power
to detect a 10 % difference in ‘success rate’ of IOP (defined
as ≥25 % reduction in baseline IOP) in the SLT group
compared with topical medication using a two-sided log-
rank test at the 5 % significance level.
Side-effects reporting and quantification
Information about transient ocular discomfort and pain;
mild uveitis; IOP spikes; the presence/absence and sever-
ity of ocular surface disease (OSD) signs and symptoms;
anterior chamber reaction (cells and flare 1 hour post-
laser) and any other sight threatening and non-sight
threatening adverse events will be collected. IOP spikes
are defined as an elevation >30 mmHg or >30 % increase
within the first 4 weeks post-treatment. The presence or
absence of OSD signs and symptoms will be obtained
from the results of the biomicroscopy, in particular, con-
cerning whether any hyperaemia and/or superficial punc-
tate epitheliopathy is present and the extent of this and
also from the responses provided by participants to the
OSD Index Questionnaire. This questionnaire was devel-
oped by Allergan, Inc’s Outcomes Research Group to
provide a rapid assessment of the severity of symptoms of
OSD and their impact on vision-related function and has
been validated in English speaking subjects [48]. We
obtained permission to use this questionnaire.
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An adverse event (AE) is defined as any untoward
medical occurrence in a patient administered therapy
that does not necessarily have a causal relationship with
this treatment. An AE can therefore also be any
unfavourable and unintended sign (including an abnor-
mal laboratory finding), symptom, or disease temporally
associated with the use of a therapy, whether or not it is
related to the therapy itself. Any AE will be recorded on
the appropriate case report form. It will be graded by an
Investigator at each site for severity and relationship to
study treatment. An AE reporting system will be imple-
mented to ascertain the occurrence of both anticipated
and unanticipated AEs. When indicated, patients suffer-
ing AEs will be referred for appropriate ophthalmic or
medical care. Information regarding AEs (including
incidence, duration, seriousness, severity, relationship to
treatment, and action taken) will be recorded through-
out the 2 years of the study. If AEs occur, the first
concern will be the study participant’s safety. To de-
termine the relationship (if any) between an AE and the
study intervention, a causal relationship is deemed
present if a determination is made that there is a reason-
able possibility that the AE may have been caused by the
intervention.
Safety data will be compiled every 6 months by the
unmasked investigator and coordinator and submitted
to the Study Project Manager, who will, in turn, for-
ward it to the Data Safety Monitoring Committee
(DSMC) for review at 6-month intervals. All AEs that
are therapy related and unexpected will also be re-
ported to the site’s Human Research Ethics Committee
(HREC).
A serious AE (SAE) will be defined as any AE that
results in any of the following outcomes: death, a life-
threatening AE, inpatient hospitalization or prolongation
of existing hospitalization, a persistent or significant dis-
ability/incapacity, or a congenital anomaly/birth defect.
Important medical events that may not result in death,
be life threatening, or require hospitalization may be
considered SAE events when, based upon appropriate
medical judgment, they may jeopardise the patient and
may require medical or surgical intervention to prevent
one of the outcomes listed in this definition. Any SAE
occurring during the study period and for at least 28
days after the last administration of therapy will be re-
ported as soon as possible to the Study Project manager
and also recorded on the appropriate case report forms.
All participants with a SAE will be followed up and
the outcomes reported. For other SAEs, the governing
HREC will be notified as required by their regulations.
The investigator will supply the Project Manager and
the HREC with any additional requested information
(for example, autopsy reports and terminal medical
reports).
Ethical issues
Ethics committee approval
This study has been approved by the HREC of the Royal
Victorian Eye and Ear Hospital (Reference number 11/
1024H), Westmead Hospital (Reference number 2011/
10/4.1 (3391) AU RED HREC/11/WMEAD/229), the
Royal Australian and New Zealand College of Ophthal-
mologists (Reference number 34.11), the Health and Dis-
ability Ethics Committees of New Zealand (Reference
number 12/STH/13), the Southern Adelaide Clinical
Human Research Ethics Committee (Reference number
81.13) and National Research Ethics Services Cambridge
East (Reference number 13/EE/0204) the Australian Col-
lege of Optometry Human Research Ethics Committee
(Ref H13 002).
Discussion
Glaucoma has a substantial impact on QoL, with patients
experiencing difficulty participating in daily activities; and
poor emotional and social well-being. In addition, there
are issues associated with the inconvenience, side effects,
and costs of treatment [3, 4, 29–34]. At present, it remains
unclear whether topical medical therapy or SLT should be
recommended as first-line treatment for glaucoma from
patient-centred and economic perspectives. We hypothe-
sise that SLT treatment will demonstrate fewer ocular and
systemic side effects and is more cost-effective than top-
ical medical therapy in the treatment of POAG and XFG.
We will determine this through a multi-centre RCT.
Because our eligibility criteria stipulate that patients
must have previously untreated glaucoma, we recognise
that we may have difficulty meeting our recruitment tar-
gets at a single site. Moreover, the coordinating site,
namely the Royal Victorian Eye and Ear Hospital, is a
tertiary eye hospital which tends to treat patients with
advanced glaucoma with well-established treatment regi-
mens. Therefore, we are collaborating with multiple
sites, both nationally and internationally, to ensure that
we reach our desired sample size. This will require site-
specific ethics approval from all additional recruitment
sites and we are aware that this will increase the amount
of time required to set-up and commence the project.
Given that our primary outcome is HRQOL which is
assessed by three patient-reported outcome measures,
the interview schedule is likely to be quite intensive for
participants. In order to reduce participant burden and
avoid fatigue, which may compromise data quality, we
will ensure participants are offered regular breaks and
the required time to complete the interview. It is also pos-
sible that participants may drop out of the study due to
the high level of participation required, which is a threat
to external validity. Therefore, all recruiters, research
assistants, and study coordinators have been trained in
techniques to optimise retention rates. These include
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communication strategies to emphasise the benefits of
participation, neutralise ambivalence, and respond to
patient-centred needs; providing reimbursement for
travel expenses; being flexible in assessment times; de-
veloping rapport with participants and family members;
and maintaining a good tracking system to monitor
follow up throughout the study period [49, 50].
This is the first multi-centred RCT to address the is-
sues that have plagued the traditional management of
glaucoma using topical medication, and it has the poten-
tial to transform our current approach to glaucoma
management. The outcome of this trial will also have a
significant economic impact on the treatment of glau-
coma considering the considerable annual cost of glau-
coma in Australia [51]. If SLT proves to be cost effective,
multi-billion dollar savings could be achieved. Our trial
will therefore have an unprecedented capacity to mean-
ingfully change and transform the treatment and man-
agement of glaucoma in Australia and overseas.
Trial status
The GITS trial started January 2013 and is expected to
finish December 2016.
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